- Home
- KLRS vs BTAI Comparison
KLRS vs BTAI Comparison
Compare KLRS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- BTAI
- Stock Information
- Founded
- KLRS 2019
- BTAI 2017
- Country
- KLRS United States
- BTAI United States
- Employees
- KLRS N/A
- BTAI N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- KLRS Health Care
- BTAI Health Care
- Exchange
- KLRS Nasdaq
- BTAI Nasdaq
- Market Cap
- KLRS 46.0M
- BTAI 52.7M
- IPO Year
- KLRS N/A
- BTAI 2018
- Fundamental
- Price
- KLRS $3.71
- BTAI $3.17
- Analyst Decision
- KLRS Strong Buy
- BTAI Buy
- Analyst Count
- KLRS 2
- BTAI 5
- Target Price
- KLRS $23.00
- BTAI $32.80
- AVG Volume (30 Days)
- KLRS 689.3K
- BTAI 7.2M
- Earning Date
- KLRS 11-15-2025
- BTAI 11-13-2025
- Dividend Yield
- KLRS N/A
- BTAI N/A
- EPS Growth
- KLRS N/A
- BTAI N/A
- EPS
- KLRS N/A
- BTAI N/A
- Revenue
- KLRS N/A
- BTAI $868,000.00
- Revenue This Year
- KLRS N/A
- BTAI N/A
- Revenue Next Year
- KLRS N/A
- BTAI $614.78
- P/E Ratio
- KLRS N/A
- BTAI N/A
- Revenue Growth
- KLRS N/A
- BTAI N/A
- 52 Week Low
- KLRS $2.14
- BTAI $1.17
- 52 Week High
- KLRS $24.15
- BTAI $13.36
- Technical
- Relative Strength Index (RSI)
- KLRS 52.79
- BTAI 42.35
- Support Level
- KLRS $2.37
- BTAI $3.41
- Resistance Level
- KLRS $4.90
- BTAI $3.95
- Average True Range (ATR)
- KLRS 0.70
- BTAI 0.46
- MACD
- KLRS -0.02
- BTAI -0.21
- Stochastic Oscillator
- KLRS 24.95
- BTAI 11.11
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.